F Xiao, Y Cheng, JR Wang,
D Wang, Y Zhang, K Chen… - Pharmaceutics, 2022 - mdpi.com
Bexarotene (BEX) was approved by the FDA in 1999 for the treatment of cutaneous T-cell
lymphoma (CTCL). The poor aqueous solubility causes the low bioavailability of the drug …